We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ALQGC market cap is 5.03M. The company's latest EPS is EUR -0.0455 and P/E is -1.54.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 10k | 2.26M | 3.16M | 3.02M | 36k |
| Operating Income | -10.47M | -13.54M | -18.72M | -30.08M | -3.14M |
| Net Income | -9.08M | -11.54M | -16.56M | -24.94M | -3.17M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 15.11M | 34.95M | 22.59M | 23.66M | 3.75M |
| Total Liabilities | 4.94M | 7.82M | 11.16M | 20.01M | 3.31M |
| Total Equity | 10.17M | 27.14M | 11.43M | 3.65M | 436k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -10.67M | -11.96M | -16.86M | -20.21M | N/A |
| Investing | -13k | -581k | -28k | -153k | N/A |
| Financing | 7.05M | 28.53M | 3.29M | 17.21M | N/A |
| Market Cap | 5.03M |
| Price to Earnings Ratio | -1.54 |
| Price to Sales Ratio | 140 |
| Price to Cash Ratio | 1.38 |
| Price to Book Ratio | 11.19 |
| Dividend Yield | - |
| Shares Outstanding | 69.71M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -28.04% |
| 52 Week High | 0.1578 |
| 52 Week Low | 0.001 |
| Spread (Intraday) | -0 (-2.64%) |
| Company Name | Quantum Genomics |
| Address |
6, rue cambaceres paris, paris 75008 |
| Website | https://quantum-genomics.com/societe/ |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
